Eunike Velleuer

Dr. Eunike Velleuer

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2005 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
OLOrna Levran
Orna Levran
CAClaire Attwooll
Claire Attwooll
RHRashida T Henry
Rashida T Henry
KMKelly L Milton
Kelly L Milton
KNKornelia Neveling
Kornelia Neveling
AAArleen D Auerbach
Arleen D Auerbach

18 December 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
NANajim Ameziane
Najim Ameziane
Patrick MayPatrick May
Patrick May
AHAnneke Haitjema
Anneke Haitjema
HVHenri J. van de Vrugt
Henri J. van de Vrugt
SRSari E. van Rossum-Fikkert
Sari E. van Rossum-Fikkert
JDJosephine C. Dorsman
Josephine C. Dorsman
Fanconi anaemia (FA) is a hereditary disease featuring hypersensitivity to DNA cross-linker-induced chromosomal instability in association with developmental abnormalities, bone marrow failure and a strong predisposition to cancer. A total of 17 FA disease genes have been reported, all of which act in a recessive mode of inheritance. Here we report on a de novo g.41022153G>A; p.Ala293Thr (NM_002875) missense mutation in one allele of the homologous recombination DNA repair gene RAD51 in an FA-like patient. This heterozygous mutation causes a novel FA subtype, ‘FA-R’, which appears to be the first subtype of FA caused by a dominant-negative mutation. The patient, who features microcephaly and mental retardation, has reached adulthood without the typical bone marrow failure and paediatric cancers. Together with the recent reports on RAD51-associated congenital mirror movement disorders, our results point to an important role for RAD51-mediated homologous recombination in neurodevelopment, in addition to DNA repair and cancer susceptibility.

1 February 2022 in Biochemical Pharmacology
Verified
Journal Article
Open access
Carsten CarlbergCarsten Carlberg
Carsten Carlberg
EVEunike Velleuer
Eunike Velleuer
Uncontrolled overgrowth of cells, such as in cancer, is an unavoidable risk in life that affects nearly every second individual in industrialized countries. However, in part this risk can be controlled through lifestyle adjustments, such as the avoidance of smoking, unhealthy diet, obesity, physical inactivity and other cancer risk factors. A low vitaminD status is a risk in particular for cancers of colon, prostate, breast and leukocytes. VitaminD3 is produced non-enzymatically, when the cholesterol precursor 7-dehydrocholesterol is exposed to UV-B from sunlight, i.e., all cholesterol synthesizing species, including humans, can make vitaminD3. VitaminD endocrinology started some 550million years ago, when the metabolite 1α,25-dihydroxyvitaminD3 and the transcription factor vitaminD receptor teamed up for regulating the expression of hundreds of target genes in a multitude of different tissues and cell types. Initially, these genes were focused on the control of energy homeostasis, which later also involved energy-demanding innate and adaptive immunity. Rapidly growing cells of the immune system as well as those of malignant tumors rely on comparable genes and pathways, some of which are modulated by vitaminD. Accordingly, vitaminD has anti-cancer effects both directly via controling the differentiation, proliferation and apoptosis of neoplastic cells as well as indirectly through regulating immune cells that belong to the microenvironment of malignant tumors. This review discusses effects of vitaminD on the epigenome and transcriptome of stromal and tumor cells, inter-individual variations in vitaminD responsiveness and their relation to the prevention and possible therapy of cancer.

19 November 2008 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
HZHester J. T. van Zeeburg
Hester J. T. van Zeeburg
PSPeter J. F. Snijders
Peter J. F. Snijders
TWThijs Wu
Thijs Wu
EGEliane Gluckman
Eliane Gluckman
JSJean Soulier
Jean Soulier
RBRuud H. Brakenhoff
Ruud H. Brakenhoff
Fanconi anemia is a recessively inherited disease that is characterized by congenital abnormalities, bone marrow failure, and a predisposition to develop cancer, particularly squamous cell carcinomas (SCCs) in the head and neck and anogenital regions. Previous studies of Fanconi anemia SCCs, mainly from US patients, revealed the presence of high-risk human papillomavirus (HPV) DNA in 21 (84%) of 25 tumors analyzed. We examined a panel of 21 SCCs mainly from European Fanconi anemia patients (n = 19 FA patients; 16 head and neck squamous cell carcinomas [HNSCCs], 2 esophageal SCCs, and 3 anogenital SCCs) for their clinical and molecular characteristics, including patterns of allelic loss, TP53 mutations, and the presence of HPV DNA by GP5+/6+ polymerase chain reaction. HPV DNA was detected in only two (10%) of 21 tumors (both anogenital SCCs) but in none of the 16 HNSCCs. Of the 18 tumors analyzed, 10 contained a TP53 mutation. The patterns of allelic loss were comparable to those generally found in sporadic SCCs. Our data show that HPV does not play a major role in squamous cell carcinogenesis in this cohort of Fanconi anemia patients and that the Fanconi anemia SCCs are genetically similar to sporadic SCCs despite having a different etiology.

30 November 2022 in Nature
Verified
Journal Article
Closed access
PDF file
AWAndrew L. H. Webster
Andrew L. H. Webster
MSMathijs A. Sanders
Mathijs A. Sanders
KPKrupa Patel
Krupa Patel
RDRalf Dietrich
Ralf Dietrich
RNRaymond J. Noonan
Raymond J. Noonan
ASAgata Smogorzewska
Agata Smogorzewska

12 October 2006 in Nature Reviews Cancer
Verified
Journal Article
Closed access
Stephan LobitzStephan Lobitz
Stephan Lobitz
EVEunike Velleuer
Eunike Velleuer